Skip to main content

Lung cancer

News and opinion

16-08-2019 | EMA | News

EMA adopts new indications for pembrolizumab, atezolizumab

Click through to find out which additional patient groups can now receive these drugs

14-08-2019 | Non-small cell lung cancer | News

Nivolumab shows long-term clinical efficacy in Japanese patients with advanced NSCLC

Pooled long-term results from two multicenter phase II studies indicate that nivolumab is efficacious in Japanese patients with previously treated, stage IIIB/IV squamous or nonsquamous non-small-cell lung cancer.

12-08-2019 | Checkpoint blockade | News

Individuals with autoimmune disease ‘good candidates’ for cancer immunotherapy

A French database analysis lends further support for the use immune checkpoint inhibitors for cancer in patients with pre-existing autoimmune disease.

07-08-2019 | EMA | News

Larotrectinib first tumor-agnostic treatment to get EMA nod

Click through for the details of this decision

02-08-2019 | Non-small cell lung cancer | News

LIPI score associated with survival in metastatic NSCLC irrespective of treatment

An exploratory pooled analysis indicates that the Lung Immune Prognostic Index score is associated with overall survival and progression-free survival in metastatic non-small-cell lung cancer patients receiving immune checkpoint inhibitors, targeted therapy, or cytotoxic chemotherapy.

31-07-2019 | Nivolumab | News

Durable survival with nivolumab in patients with advanced RCC, NSCLC

Five-year data from the phase I CA209-003 trial indicate that the PD-1 inhibitor nivolumab is associated with long-term survival benefits among heavily pretreated patients with advanced renal cell carcinoma or non-small-cell lung cancer.

26-07-2019 | Non-small cell lung cancer | News

Hurricane disruption quantified for lung cancer radiotherapy

Hurricane disasters significantly and adversely impact the overall survival of patients undergoing definitive radiotherapy for locally advanced non-small-cell lung cancer, study findings suggest.

24-07-2019 | Non-small cell lung cancer | News

HBV reactivation risk ‘moderate to high’ for EGRF–TKI-treated NSCLC

Patients with non-small-cell lung cancer undergoing treatment with an EGFR–tyrosine kinase inhibitor may have a clinically meaningful risk for reactivation of unresolved hepatitis B virus infection during treatment, study findings indicate.

22-07-2019 | Non-small cell lung cancer | News

Local ablative therapy–pembrolizumab benefit suggested for metastatic NSCLC

Data from two phase II studies published in JAMA Oncology lend support to the sequential use of local ablative therapy and PD-1 blockade in patients with metastatic non-small-cell lung cancer.

18-07-2019 | Non-small cell lung cancer | News

Genomic markers of brain metastasis risk identified in NSCLC

Researchers have identified key genomic alterations in brain metastases matched to primary non-small-cell lung cancer that could serve as prognostic markers and potential therapeutic targets.

16-07-2019 | Ramucirumab | News

Phase I data support dual VEGFR2, PD-1 inhibition

Phase I study data suggest that ramucirumab plus pembrolizumab is a feasible treatment option for patients with previously treated advanced non-small-cell lung cancer, urothelial carcinoma, and gastric or gastroesophageal junction adenocarcinoma.

12-07-2019 | Screening | News

Low-dose CT provides superior screening for lung cancer death in high-risk smokers

Findings from an extended follow-up of the National Lung Screening Trial maintain that low-dose computed tomography screening significantly reduces risk for lung cancer death versus chest radiography screening among high-risk current and former smokers.

09-07-2019 | Non-small cell lung cancer | News

Vemurafenib monotherapy has potential for BRAF-mutated NSCLC

Single-agent vemurafenib has demonstrated promising antitumor activity against non-small-cell lung cancer harboring BRAF V600E mutations in the VE-BASKET trial.

08-07-2019 | Screening | Highlight | News

Expansion of USPSTF lung screening criteria warranted

Results from two studies suggest that the current US Preventive Services Task Force lung cancer screening criteria may exclude certain individuals who could benefit from screening.

03-07-2019 | Immunotherapy | News

Steroid indication plays key role in link to poor immunotherapy outcome

Poor outcomes among patients with non-small-cell lung cancer who receive corticosteroids prior to immunotherapy are driven by the use of steroids for palliative oncologic symptom management, study findings indicate.

28-06-2019 | Immunotherapy | Highlight | News

Checkpoint inhibitor rechallenge feasible after irAE-related discontinuation

Two studies point to the feasibility of resuming immune checkpoint inhibitors in patients who discontinue treatment due to immune-related adverse events.

27-06-2019 | Non-small cell lung cancer | News

Chest radiation increases cardiac risk in NSCLC patients

Patients with locally advanced non-small-cell lung cancer have a high risk for major adverse cardiac events after radiotherapy that may warrant a reduction in cardiac radiation dose, study findings indicate.

25-06-2019 | FDA | News

Pembrolizumab approved in USA for metastatic SCLC

Click through for the details of this FDA decision

24-06-2019 | Non-small cell lung cancer | ASCO 2019 | News

Adding chemotherapy to gefitinib improves EGFR-mutated NSCLC outcomes

Supplementing the EGFR–tyrosine kinase inhibitor gefitinib with pemetrexed and carboplatin doubles progression-free survival in patients with advanced, chemotherapy-naïve non-small-cell lung cancer harboring activating EGFR mutations, according to phase III results.

21-06-2019 | Non-small cell lung cancer | ASCO 2019 | News

Neoadjuvant immunotherapy shows promise for resectable NSCLC

Neoadjuvant immunotherapy produces encouraging major pathologic response rates among patients with resectable non-small-cell lung cancer, show data presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

Image Credits